Clinical trial software provider ProofPilot has raised over $12m in a Series B funding round led by Mitsui. The financing round saw participation from Sopris Capital, First Trust Capital Partners, and Excelra among others.

Established in 2014, ProofPilot is a Software as a Service (SaaS) clinical trial research platform.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Making trials inexpensive and simple, the company permits various companies to assess their next-generation healthcare solutions and extend to various groups of subjects.

It provides solutions to the complicated clinical trial market by providing a completely digitised platform with trial process management, self-design study and remote source verification expertise. 

ProofPilot is changing the standard trial model allowing more firms to afford to carry out trials on a broader range of regulated and non-regulated products and services, without needing traditional internal infrastructure. 

This transformation will aid small companies in designing and conducting trials rigorously and substantially boost the research capability of life science firms.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Wellville executive founder Esther Dyson will join the board of directors of ProofPilot as part of the funding. 

ProofPilot’s SaaS product allows users to create, launch, participate and engage in research studies. 

ProofPilot CEO and co-founder Matthew Amsden said: “Through our cost-effective and digitally-enabled platform, pharmaceutical and medical device companies can expand the efficacies of their existing products and explore the potential of digital health solutions. 

“For the first time, health & wellness companies can now access clinical trials to substantiate their products and services at a manageable cost. 

“Moreover, participants can seamlessly engage in clinical trial support.”

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact